title: The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients.
abstract: Understanding the causes of diabetic vascular complications has become an increasingly important issue because of the rapidly rising prevalence of diabetes. Recently discovered vasoconstrictors and angiogenesis regulators, such as endothelin (ET) and vascular endothelial growth factor (VEGF), have been intensely studied for possible pathogenic roles in diabetic vascular complications. The present study was undertaken to clarify the effect of glycemic control on serum VEGF and plasma ET-1 concentrations in diabetic patients, and to identify other factors that may cause fluctuations of these substances. Plasma VEGF and ET-1 concentrations of 45 hospitalized diabetic patients and 54 control subjects were measured by enzyme immunoassay (EIA) and radioimmunoassay (RIA), respectively. Plasma VEGF was elevated in poorly controlled diabetic patients compared with healthy subjects and plasma VEGF concentrations declined after hospitalized treatment with either insulin or oral hypoglycemic agents in combination with diet. There was a significant correlation between plasma VEGF concentration and both fasting plasma glucose (FPG) and hemoglobin A(1c) (HbA(1c)). Plasma ET-1 in poorly controlled diabetic patients was higher than in healthy controls, but improved glycemic control did not affect plasma ET-1 concentrations. Thus, poor glycemic control causes increased levels of plasma VEGF, which may result in hypertension and vascular complications in diabetes. Short-term treatment resulting in good glycemic control can improve levels of VEGF and may provide beneficial effects on diabetic vascular complications.
authors.affiliation: Department of Internal Medicine, Fujita Health University, School of Medicine, Aichi, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kakizawa
authors.forename: Mitsuyasu
authors.initials: M
authors.lastname: Itoh
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Itoh
authors.forename: Shigeo
authors.initials: S
authors.lastname: Imamura
authors.forename: Yoko
authors.initials: Y
authors.lastname: Ishiwata
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Keiko
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Taiya
authors.initials: T
authors.lastname: Kato
authors.forename: Yasunaga
authors.initials: Y
authors.lastname: Ono
authors.forename: Mutsuko
authors.initials: M
authors.lastname: Nagata
authors.forename: Nobuki
authors.initials: N
authors.lastname: Hayakawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Suzuki
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Goto
authors.forename: Naohisa
authors.initials: N
authors.lastname: Oda
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D016022:Case-Control Studies; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D003929:Diabetic Neuropathies / Q000097:blood; D003930:Diabetic Retinopathy / Q000097:blood; D019332:Endothelin-1 / Q000097:blood*; D005215:Fasting / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000097:blood; D012044:Regression Analysis; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D001786:Blood Glucose; D019332:Endothelin-1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D042461:Vascular Endothelial Growth Factor A